company background image
SYNGENE logo

Syngene International NSEI:SYNGENE Stock Report

Last Price

₹849.95

Market Cap

₹344.9b

7D

-2.3%

1Y

24.5%

Updated

19 Dec, 2024

Data

Company Financials +

Syngene International Limited

NSEI:SYNGENE Stock Report

Market Cap: ₹344.9b

SYNGENE Stock Overview

A contract research and manufacturing company, provides drug discovery and development services in India, the United States of America, Europe, and internationally. More details

SYNGENE fundamental analysis
Snowflake Score
Valuation0/6
Future Growth3/6
Past Performance2/6
Financial Health6/6
Dividends2/6

Rewards

Earnings are forecast to grow 19.32% per year

Risk Analysis

Significant insider selling over the past 3 months


My Notes

Capture your thoughts, links and company narrative

Community Narratives

Create a narrative

Narratives bring a range of perspectives from our community.

WA
Analyst Price Target
Consensus Narrative from 8 Analysts

Company's Biologics Expansion And Automation Drive Robust Revenue Growth Ahead

Key Takeaways Early recovery in Discovery Services and biologics manufacturing could lead to significant revenue growth from new collaborations and operational facilities. Strategic investments in automation, digital transformation, and sophisticated drug modalities can drive operational efficiencies and high-margin revenue opportunities.
View narrative
₹862.50
FV
1.5% undervalued intrinsic discount
17.21%
Revenue growth p.a.
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
2 days ago author updated this narrative

Syngene International Limited Competitors

Indegene

NSEI:INDGN

₹145.1b

Akums Drugs and Pharmaceuticals

NSEI:AKUMS

₹88.2b

Divi's Laboratories

NSEI:DIVISLAB

₹1.5t

Innova Captab

NSEI:INNOVACAP

₹58.2b

Price History & Performance

Summary of share price highs, lows and changes for Syngene International
Historical stock prices
Current Share Price₹849.95
52 Week High₹960.60
52 Week Low₹607.65
Beta0.58
1 Month Change-0.10%
3 Month Change-6.58%
1 Year Change24.52%
3 Year Change38.52%
5 Year Change173.56%
Change since IPO447.38%

Recent News & Updates

Why Syngene International's (NSE:SYNGENE) Shaky Earnings Are Just The Beginning Of Its Problems

Oct 31
Why Syngene International's (NSE:SYNGENE) Shaky Earnings Are Just The Beginning Of Its Problems

Recent updates

Why Syngene International's (NSE:SYNGENE) Shaky Earnings Are Just The Beginning Of Its Problems

Oct 31
Why Syngene International's (NSE:SYNGENE) Shaky Earnings Are Just The Beginning Of Its Problems

Syngene International Limited's (NSE:SYNGENE) Popularity With Investors Is Under Threat From Overpricing

Jul 16
Syngene International Limited's (NSE:SYNGENE) Popularity With Investors Is Under Threat From Overpricing

These 4 Measures Indicate That Syngene International (NSE:SYNGENE) Is Using Debt Safely

Mar 28
These 4 Measures Indicate That Syngene International (NSE:SYNGENE) Is Using Debt Safely

Do Syngene International's (NSE:SYNGENE) Earnings Warrant Your Attention?

Feb 14
Do Syngene International's (NSE:SYNGENE) Earnings Warrant Your Attention?

Earnings Not Telling The Story For Syngene International Limited (NSE:SYNGENE)

Jan 19
Earnings Not Telling The Story For Syngene International Limited (NSE:SYNGENE)

Is Syngene International (NSE:SYNGENE) A Risky Investment?

Nov 19
Is Syngene International (NSE:SYNGENE) A Risky Investment?

Is Now The Time To Put Syngene International (NSE:SYNGENE) On Your Watchlist?

Nov 01
Is Now The Time To Put Syngene International (NSE:SYNGENE) On Your Watchlist?

Syngene International (NSE:SYNGENE) Seems To Use Debt Rather Sparingly

Aug 07
Syngene International (NSE:SYNGENE) Seems To Use Debt Rather Sparingly

These 4 Measures Indicate That Syngene International (NSE:SYNGENE) Is Using Debt Safely

Apr 28
These 4 Measures Indicate That Syngene International (NSE:SYNGENE) Is Using Debt Safely

Here's Why We Think Syngene International (NSE:SYNGENE) Is Well Worth Watching

Apr 06
Here's Why We Think Syngene International (NSE:SYNGENE) Is Well Worth Watching

Does Syngene International (NSE:SYNGENE) Deserve A Spot On Your Watchlist?

Jan 04
Does Syngene International (NSE:SYNGENE) Deserve A Spot On Your Watchlist?

Syngene International (NSE:SYNGENE) Has A Pretty Healthy Balance Sheet

Dec 08
Syngene International (NSE:SYNGENE) Has A Pretty Healthy Balance Sheet

Is Syngene International (NSE:SYNGENE) Using Too Much Debt?

Aug 28
Is Syngene International (NSE:SYNGENE) Using Too Much Debt?

Syngene International Limited (NSE:SYNGENE) Shares Could Be 22% Above Their Intrinsic Value Estimate

Aug 10
Syngene International Limited (NSE:SYNGENE) Shares Could Be 22% Above Their Intrinsic Value Estimate

These 4 Measures Indicate That Syngene International (NSE:SYNGENE) Is Using Debt Reasonably Well

May 10
These 4 Measures Indicate That Syngene International (NSE:SYNGENE) Is Using Debt Reasonably Well

Shareholder Returns

SYNGENEIN Life SciencesIN Market
7D-2.3%-2.2%-1.9%
1Y24.5%54.0%24.7%

Return vs Industry: SYNGENE underperformed the Indian Life Sciences industry which returned 54% over the past year.

Return vs Market: SYNGENE matched the Indian Market which returned 24.7% over the past year.

Price Volatility

Is SYNGENE's price volatile compared to industry and market?
SYNGENE volatility
SYNGENE Average Weekly Movement4.1%
Life Sciences Industry Average Movement6.2%
Market Average Movement6.2%
10% most volatile stocks in IN Market9.1%
10% least volatile stocks in IN Market4.1%

Stable Share Price: SYNGENE has not had significant price volatility in the past 3 months compared to the Indian market.

Volatility Over Time: SYNGENE's weekly volatility (4%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19936,510Jonathan Huntwww.syngeneintl.com

Syngene International Limited, a contract research and manufacturing company, provides drug discovery and development services in India, the United States of America, Europe, and internationally. The company provides discovery chemistry services, such as synthetic and medicinal chemistry, library and peptide synthesis, biomolecular science, organic electronic materials, and computational and analytical chemistry; discovery biology services in the areas of recombinant DNA engineering, cell line development, hybridoma technology, sequencing, protein sciences, screening and assay biology, DMPK, in vivo pharmacology, toxicology, and biologicals; and chemical, formulation, analytical, and clinical development services, as well as commercial manufacturing and sterile fill-finish services. It also provides lead generation, preclinical development, API, and drug product development services; and clinical trial management, pharmacokinetic analysis/bioanalytical studies, biometrics and clinical data management, central lab, regulatory, medical monitoring, pharmacovigilance, and medical writing services.

Syngene International Limited Fundamentals Summary

How do Syngene International's earnings and revenue compare to its market cap?
SYNGENE fundamental statistics
Market cap₹344.88b
Earnings (TTM)₹4.82b
Revenue (TTM)₹34.51b

70.8x

P/E Ratio

9.9x

P/S Ratio

Is SYNGENE overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
SYNGENE income statement (TTM)
Revenue₹34.51b
Cost of Revenue₹11.19b
Gross Profit₹23.32b
Other Expenses₹18.51b
Earnings₹4.82b

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)12.01
Gross Margin67.58%
Net Profit Margin13.96%
Debt/Equity Ratio3.6%

How did SYNGENE perform over the long term?

See historical performance and comparison

Dividends

0.1%

Current Dividend Yield

10%

Payout Ratio

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/19 14:20
End of Day Share Price 2024/12/19 00:00
Earnings2024/09/30
Annual Earnings2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Syngene International Limited is covered by 21 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
null nullAsian Markets Securities Private Limited
Harith AhamedAvendus Spark
Prakash AgarwalAxis Capital Limited